NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

Former President Biden said the country is in the midst of “dark days” under President Trump. “Friends, I can’t sugar coat any of this. These are dark days,” Biden said in Boston on Sunday after ...

GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).

GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.